Nature 452, 872-876 (17 April 2008) | doi:10.1038/nature06884; Received 3 December 2007; Accepted 4 March 2008

The complete genome of an individual by massively parallel DNA sequencing

See associated Correspondence: Roche, Nature 453, 281 (May 2008)

David A. Wheeler1,7, Maithreyan Srinivasan2,7, Michael Egholm2,7, Yufeng Shen1,7, Lei Chen1, Amy McGuire3, Wen He2, Yi-Ju Chen2, Vinod Makhijani2, G. Thomas Roth2, Xavier Gomes2, Karrie Tartaro2,8, Faheem Niazi2, Cynthia L. Turcotte2, Gerard P. Irzyk2, James R. Lupski4,5,6, Craig Chinault4, Xing-zhi Song1, Yue Liu1, Ye Yuan1, Lynne Nazareth1, Xiang Qin1, Donna M. Muzny1, Marcel Margulies2, George M. Weinstock1,4, Richard A. Gibbs1,4 & Jonathan M. Rothberg2,8

  1. Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
  2. 454 Life Sciences, Roche Diagnostics, 20 Commercial Street, Bradford, Connecticut 06405, USA
  3. Center for Ethics and Health Policy, Baylor College of Medicine, One Baylor Plaza, Houston Texas 77030, USA
  4. Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston Texas 77030, USA
  5. Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza, Houston Texas 77030, USA
  6. Texas Children’s Hospital, Texas Medical Center, Houston, Texas 77030, USA
  7. These authors contributed equally to this work.
  8. Present addresses: Molecular Imaging Systems, Carestream Health, Inc., 4Science Park, New Haven, Connecticut 06511, USA (K.T.); Rothberg Institute for Childhood Diseases, 530 Whitfield Street, Guilford, Connecticut 06437, USA (J.M.R.).

Correspondence to: Richard A. Gibbs1,4Jonathan M. Rothberg2,8 Correspondence and requests for materials should be addressed to J.M.R. (Email: jonathan.rothberg@gmail.com) or R.A.G. (Email: agibbs@bcm.tmc.edu).

This article is distributed under the terms of the Creative Commons Attribution-Non-Commercial-Share Alike licence (http://creativecommons.org/licenses/by-nc-sa/3.0/), which permits distribution, and reproduction in any medium, provided the original author and source are credited. This licence does not permit commercial exploitation, and derivative works must be licensed under the same or similar licence.


The association of genetic variation with disease and drug response, and improvements in nucleic acid technologies, have given great optimism for the impact of ‘genomic medicine’. However, the formidable size of the diploid human genome1, approximately 6gigabases, has prevented the routine application of sequencing methods to deciphering complete individual human genomes. To realize the full potential of genomics for human health, this limitation must be overcome. Here we report the DNA sequence of a diploid genome of a single individual, James D. Watson, sequenced to 7.4-fold redundancy in two months using massively parallel sequencing in picolitre-size reaction vessels. This sequence was completed in two months at approximately one-hundredth of the cost of traditional capillary electrophoresis methods. Comparison of the sequence to the reference genome led to the identification of 3.3million single nucleotide polymorphisms, of which 10,654 cause amino-acid substitution within the coding sequence. In addition, we accurately identified small-scale (2–40,000 base pair (bp)) insertion and deletion polymorphism as well as copy number variation resulting in the large-scale gain and loss of chromosomal segments ranging from 26,000 to 1.5million base pairs. Overall, these results agree well with recent results of sequencing of a single individual2 by traditional methods. However, in addition to being faster and significantly less expensive, this sequencing technology avoids the arbitrary loss of genomic sequences inherent in random shotgun sequencing by bacterial cloning because it amplifies DNA in a cell-free system. As a result, we further demonstrate the acquisition of novel human sequence, including novel genes not previously identified by traditional genomic sequencing. This is the first genome sequenced by next-generation technologies. Therefore it is a pilot for the future challenges of ‘personalized genome sequencing’.

To catalogue the genomic diversity within a single individual, a total of 106.5million high-quality reads were generated by 454-sequencing3, representing approximately 24.5billion DNA bases. Reads that aligned to the genome were further filtered using stringent criteria to ensure the accuracy of mapping, resulting in 93.2million reads aligned to reference genome sequence. The reference genome sequence was thus covered to an average depth of 7.4-fold (Fig. 1a). The alignments between the uniquely mapped reads and the reference genome were used to catalogue genetic variation in the subject’s DNA, including single nucleotide polymorphisms (SNPs), small insertions and deletions (indels), and copy number variation (CNV).

Figure 1: 454-Sequencing of individual genome generated even coverage enabling genome-wide detection of variation.
Figure 1 : 454-Sequencing of individual genome generated even coverage enabling genome-wide detection of variation. Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

a, Distribution of sequence coverage of reference genome by 454-reads is random. Coverage, calculated in consecutive 5-kb windows, exhibited a Poisson distribution with a mean of 7.4-fold across all chromosomes except the X. Shoulder at 3.7X represents coverage of the X chromosome. b, Coverage is a key factor in detection of both alleles at heterozygous positions. For 31,709 markers heterozygous by microarray, but which exhibited only a single allele by DNA sequencing, the coverage was lower (red line, mean 5.7X) than the overall coverage for all SNPs (blue line, mean 7.8X). c, Size distribution of deletions. Deletions were readily observed in alignments of 454-reads to the reference genome. Note the peak in the size range at 300–350 bases owing to polymorphic Alu transposon insertion sites.

High resolution image and legend (139K)

The 454 base-calling software provides error estimates (Q values) for each base. We developed a three-step filtering process using the patterns of error and associated Q values from the 454 base-calling software to improve the accuracy of SNP discovery. An initial 14million variant positions were filtered to 3.32million putative SNPs (Table 1).

Comparison of these putative SNPs in the subject’s genome with those in the dbSNP (dbSNP: http://www.ncbi.nlm.nih.gov/projects/SNP/) revealed 2.72million in common (‘known SNPs’). Approximately 99% of SNPs in dbSNP are bi-allelic. At only 10,425 positions did the subject’s variant not match the variant found in dbSNP. Although some of these could represent a third allele in the population, or an error in the dbSNP polymorphism record, we conservatively estimated the false discovery rate in the known SNPs to be approximately 0.38% based on the mismatches with dbSNP.

The remaining 0.61million SNPs were at positions not previously identified as polymorphic in dbSNP (‘novel SNPs’). The known SNPs were divided almost equally between homozygous (50.2%) and heterozygous (49.8%) SNPs, whereas within the novel SNPs heterozygotes predominate (83.3%) compared with homozygotes (16.7%). Because most common alleles in human populations are already captured in dbSNP, novel variants are expected to be rare, and therefore much more likely to be found as heterozygotes.

We assessed the accuracy of the known SNPs derived from DNA sequencing by comparison with the experimental genotyping of the subject’s DNA using an Affymetrix 500K microarray. Compared with a haploid reference sequence, there are four possible outcomes of SNP array genotyping: homozygous for the reference allele; homozygous for the variant (non-reference) allele; heterozygous; and assay failure. Table 2 shows the results for 494,713 markers that were successfully genotyped. The subject’s DNA sequence exhibited only the reference allele at 99.4% of the markers homozygous for the reference and at 95.1% of markers homozygous for the variant. Genotyping identified 135,413 heterozygous markers of which 75.8% exhibited two alleles in the 454-reads. The lower sensitivity of detection of heterozygotes is predicted by a Poisson process of sampling DNA fragments modelled on a diploid genome (Methods). Consistent with this model, the coverage was lower at the 24.2% of heterozygous positions where DNA sequencing represented only one of the correct alleles (Fig. 1b and Supplementary Table 2). The Poisson model further shows that 13-fold average coverage would be required to detect 99% of all heterozygous SNPs (Supplementary Fig. 4).

The DNA sequencing genotypes disagree with the SNP array genotyping in 4,948 cases, or 1.0% of the time; another 3,499 markers (0.30%) had no coverage, consistent with the genome-wide redundancy of the sequence. Assuming the sensitivity and specificity of the markers on the microarray is representative of those found throughout the human genome, we estimate the total number of SNPs in the subject’s genome to be approximately 3.7million (see ‘Sensitivity and specificity of SNP discovery’ in Supplementary Information).

We identified 222,718 indels ranging from 2 to 38,896bp, with 113,539 in common with indels in dbSNP; 85,418 indels are found as homozygotes, and 137,300 were heterozygotes. Insertions account for 65,677 events, and deletions 157,041. A portion of the deletion size distribution from 2 to 1000bp is shown in Fig. 1c. The distribution of deletions shows the relative enrichment for events in the range 300–350 bases in length, as expected from the known polymorphism of Alu SINE elements4, 5. The size range over which insertions are detected is limited by the length of the reads; in the analysis of our 250 base-pair 454-sequencing reads, the largest observed was 208bp.

A total of 345 indels were observed to overlap coding sequence and had the potential to alter protein function. We designed primers to amplify and validate by Sanger sequencing 111 of these events with a size range of 3–50 bases. A total of 78 indels were successfully validated of which 66 were observed to be in length multiples of 3, ranging from 3 to 33bp, and hence not expected to cause protein translation frame shifts. Sixty-five of these indels were found as heterozygotes. Surprisingly, a 4-bp deletion in exon 11 of SGEF was found to be homozygous; however, this gene is highly conserved in vertebrate species from rhesus macaque to stickleback, and all manifest the same 4-bp deletion in their genome (Supplementary Fig. 5). Furthermore, two other independent human messenger RNAs (mRNAs) harbour the deletion as well, suggesting the subject’s allele was the wild type and that the reference harbours a rare insertion.

CNVs are local gains or losses of regions in the genome owing to duplication or deletion that can be associated with genetic disease6 and which should be detectable by variation in the average DNA sequence coverage of the region. A comparative genomic hybridization (CGH) microarray analysis of the subject’s DNA revealed 23 apparent CNV regions ranging in size from 26kb to 1.6Mb: 9 with DNA gains and 14 with a loss. The sequence coverage data exhibited a gain or loss congruent with the CGH result at 18 of the 23 regions (Supplementary Table 4). Regions of CNV are polymorphic in populations, segregating as alleles with varying frequency7, 8. Consequently, the interpretation of a CGH microarray depends on the reference genome with which the subject is compared. This difference in reference standard is unavoidable when comparing CGH with DNA sequencing results using National Center for Biotechnology Information (NCBI) build 36 as the reference, which is not based on a single individual and for which no physical DNA sample exists. We experimentally demonstrated variation in CGH results by repeating the CGH array using a second reference genome and two different array platforms, demonstrating the effect the reference DNA has on the outcome of a CGH experiment (Supplementary Table 4).

An individual region of homozygous loss was characterized further using CGH results and DNA sequencing (Supplementary Fig. 6c). Sequence alignment of the subject’s reads spanning the breakpoint of a homozygous deletion region reveals a 2-bp addition at the breakpoint junction, suggesting non-homologous end joining6 was the mechanism involved in generating the deletion, and demonstrating the feasibility of using 454 sequence reads for identifying CNV breakpoints (Supplementary Fig. 6c). Several other CNV regions were flanked by repeats and segmental duplications, and likely occur by non-allelic homologous recombination, as was reported recently for the CNV loss at 22q13.1 (ref. 9) (see CNV 23 in Supplementary Table 4).

None of the CNV regions we defined are currently known to be involved in a recognizable phenotype; however, either trait or disease susceptibility correlations could occur in the future10. Thirty-four genes are predicted to be affected by these gains and losses, including two separate olfactory receptor groups, several genes with possible roles in cancers of the prostate, breast and colon, a gene from the HLA-D locus, and two proteins thought to be involved in RNA editing (Supplementary Table 4).

Among the 3.3million SNPs found in the subject’s genome were 8,996 non-synonymous changes in known SNPs and 1,573 in novel SNPs. We compared the non-synonymous known SNPs with the Human Gene Mutation Database (HGMD), the largest current compendium of human disease alleles11. Thirty-two alleles exactly matched mutations reported in the HGMD whereas an additional 310 of these were in HGMD genes but were either alleles or amino-acid positions not previously characterized as disease-causing. In 12 cases the specific alterations and loci consisted of genes where homozygous recessive alleles can give rise to disease or other recognizable phenotype (Table 3); and 20 cases are reported to be associations with increased disease risk (Supplementary Table 5).

Ten of the 12 alleles in Table 3 are thought to be highly penetrant, Mendelian recessive disease-causing alleles. Seven of ten were heterozygous in the subject’s genome sequence; the other three only exhibited one allele but have an average sequence coverage less than fivefold. Because the subject does not have these three diseases, and we expect not to recover the second allele for 24% of heterozygous positions, it is likely that he is not homozygous for these disease allele positions. We note that there are not yet any systematic studies of the population frequencies of these alleles. Nevertheless, the subject is a carrier for ten highly penetrant genetic disease loci found in the HGMD data set consisting of 900 genes. It has been estimated there are fewer than ten lethal equivalents in each person12, 13, 14. Because we have drawn ten from an HGMD subset of the genome, we would predict the subject harbours a much greater number of deleterious Mendelian mutant alleles than is commonly estimated.

In addition, a sampling of 3,898 of the non-synonymous SNPs were tested for their possible functional impact on the protein sequence using the software Polyphen15. Polyphen classified 7.3% as ‘probably damaging’, suggesting these changes will be of functional consequence to the protein. The remainder were classified as either ‘possibly damaging’ (13%) or ‘benign’ (74%).

The genome sequence of another individual (C.Venter) was recently reported2. That study reported a 7.5-fold genome coverage using Sanger reads. The Venter genome harboured approximately 2.8million known SNPs and about 0.74million novel SNPs, in close agreement with the results from 454-reads of the Watson genome at a similar fold coverage. The two individuals shared 1.68million of the SNPs, of which 5,230 were non-synonymous, accounting for 58% of the subject’s non-synonymous SNPs. Watson and Venter are each distinguished from the reference by 3,766 and 3,882 non-synonymous SNPs, respectively, and therefore are different from each other by 7,648 protein coding changes. This is the most comprehensive comparison of the non-synonymous difference between two diploid genomes yet undertaken.

The subject’s data also contained 1.5million reads of novel sequence that did not map to build-36, corresponding to about 1.4% of the total sequence data. Approximately 65% of the unmapped sequences matched to known human repeats enriched for satellite DNA and other repeat elements characteristic of heterochromatin (Supplementary Fig. 7). The novel reads were assembled into approximately 170,000 contigs spanning 48Mb. After removing contigs with fewer than 100bp of contiguous unique sequence, 110,000 contigs spanning 29Mb remained, which is close to the 25Mb of euchromatic sequence predicted to be absent from the reference genome1. These non-repeat contigs closely match to 33 human complementary DNA (cDNA) sequences from a variety of tissues and predicted functions (Supplementary Table 6) having no known map location on the human reference genome (see Methods). To assess further the gene-coding potential of these novel DNA sequences, we compared conceptual translations of the contigs greater than 1,000bp (1,279 in all) with the GenBank non-redundant (NR) protein database. This search yielded 60 significant, but not identical, matches to 49 different proteins in humans and other vertebrates (Supplementary Table 7). The annotations of several of these transcripts are consistent with transcription factor or signalling molecules. Therefore it is possible this diploid genome sequence will contribute important new genes to the human genome.

The sequencing method used in this study has many advantages over traditional capillary sequencing. It is inherently scalable, which means that sequencing costs in the miniature continue to decrease and throughput increases as the density of the sequencing reactions on the chip increases, and read lengths get longer3. In this study we sequenced the genome of Dr Watson for less than US$1million, whereas the genome of Venter by Sanger sequence reportedly cost approximately US$100million. Although not used in this study, this sequencing technology allows the production of mate-paired reads. The use of mate-pair reads will enable assessment of a wider range of indels and other structural rearrangements, and facilitate the incorporation of new sequence into the reference genome16. The principal weakness of the method is that it currently does not allow efficient detection of single-base indels in homopolymers. Future developments in chemistry and software will improve the ability to identify single-base indels.

A key aim of personal genome sequencing is to identify genome sequences that may be associated with disease, or are predictive of response to medication. The need to make genotype–phenotype correlations before having predictive value is at the heart of both the excitement and the dilemma of the new era of genomic medicine17. Thus the ability to sequence individuals readily using high-throughput, scaleable, low-cost, completely in vitro technology, as demonstrated here, is an important milestone in our ability to connect ‘personalized genomes’ to ‘personalized medicine’ and enable these critical correlations to be made.


Methods Summary

Mapping and alignment to the genome

DNA sequencing on the Genome Sequencer FLX instrument (454, Inc.) is described in detail in Methods. Reads, averaging approximately 250 bases, were mapped on to the human reference genome, NCBI build 36, by sequence alignment using Basic Local Alignment Search Tool (BLAST)-like alignment tool (BLAT). Reads were removed from subsequent analysis that failed to meet minimum criteria (see Methods). Reads that passed the alignment quality criteria were realigned to local reference genome fragments using Cross_match software; the refined alignments were parsed for sequence variation between the subject and the reference. An error model was developed to separate sequencing error from true genomic variation, and the location and type of each putative true variant was tabulated (see Methods).

Assembly of non-matching reads

One and a half million reads that failed to find a match in the reference genome sequence (‘no-hit’ reads) and another 2.2million reads with low-quality alignments to the reference were pooled for sequence assembly. All reads were trimmed to remove the last 50 bases in which most of the sequencing error lies. Reads less than 50 bases after trimming were discarded. The assembly of the remaining 2.6million trimmed reads followed the standard ATLAS-WGS procedure18, 19.

Laboratory analysis of genomic DNA

A DNA sample from the subject was labelled and annealed to the Affymetrix 500K GeneChip array to provide independent laboratory analysis of the subject’s SNPs and conformation of the DNA sequencing coverage. To compare local fluctuation in DNA sequencing coverage with copy number variation in the subject’s genome, three additional DNA samples were labelled and mixed each in a 1:1 ratio with separately labelled control DNAs. The mixtures were annealed to each of two Agilent 244K array CGH chips and one Nimblegen HD2 chip.

Full methods accompany this paper.



  1. The International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431, 931–945 (2004) | Article | PubMed | ISI | ChemPort |
  2. Levy, S. et al. The diploid genome sequence of a single individual. PLoS Biol. 5, e254–e286 (2007) | Article | PubMed | ChemPort |
  3. Margulies, M. et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437, 376–380 (2005) | Article | PubMed | ISI |
  4. Bennett, E. A., Coleman, L. E., Tsui, C., Pittard, W. S. & Devine, S. E. Natural genetic variation caused by transposable elements in humans. Genetics 168, 933–951 (2004) | Article | PubMed | ChemPort |
  5. The Chimpanzee Sequencing and Analysis Consortium. Initial sequence of the chimpanzee genome and comparison with the human genome. Nature 437, 69–87 (2005) | Article | PubMed | ISI | ChemPort |
  6. Lupski, J. R. & Stankiewicz, P. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genetics 1, 627–633 (2005) | Article | ChemPort |
  7. Weber, J. L. et al. Human diallelic insertion/deletion polymorphisms. Am. J. Hum. Genet. 71, 854–862 (2002) | Article | PubMed | ISI |
  8. Redon, R. et al. Global variation in copy number in the human genome. Nature 444, 444–454 (2006) | Article | PubMed | ISI | ChemPort |
  9. Kidd, J. M., Newman, T. L., Tuzun, E., Kaul, R. & Eichler, E. E. Population stratification of a common APOBEC gene deletion polymorphism. PLOS Genetics 3, 584–592 (2007) | Article | ChemPort |
  10. Lupski, J. R. Structural variation in the human genome. N. Engl. J. Med. 356, 1169–1171 (2007) | Article | PubMed | ChemPort |
  11. Stenson, P. D. et al. Human Gene Mutation Database (HGMD): 2003 update. Hum. Mutat. 21, 577–581 (2003) | Article | PubMed | ISI | ChemPort |
  12. Halligan, D. L. & Keightley, P. D. How many lethal alleles? Trends Genet. 19, 57–59 (2003) | Article | PubMed | ChemPort |
  13. Bittles, A. H. & Neel, J. V. The costs of human inbreeding and their implications for variations at the DNA level. Nature Genet. 8, 117–121 (1994) | Article |
  14. Vogel, F. & Motulsky, A. G. Human Genetics: Problems and Approaches 2nd edn 487–502 (Springer-Verlag, New York, 1986)
  15. Ramensky, V., Bork, P. & Sunyaev, S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 30, 3894–3900 (2002) | Article | PubMed | ISI | ChemPort |
  16. Korbel, J. O. et al. Paired-end mapping reveals extensive structural variation in the human genome. Science 318, 420–426 (2007) | Article | PubMed | ChemPort |
  17. McGuire, A. L., Caulfield, T. & Cho, M. K. Research ethics and the challenge of whole genome sequencing. Nature Rev. Genet. 9, 152–156 (2008) | Article |
  18. Havlak, P. et al. The Atlas genome assembly system. Genome Res. 14, 721–732 (2004) | Article | PubMed | ISI | ChemPort |
  19. Richards, S. et al. Comparative genome sequencing of Drosophila pseudoobscura: chromosomal, gene, and cis-element evolution. Genome Res. 15, 1–18 (2005) | Article | PubMed | ISI | ChemPort |
  20. Ewing, B. & Green, P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res. 8, 186–194 (1998) | PubMed | ISI | ChemPort |
  21. Lander, E. S. & Waterman, M. S. Genomic mapping by fingerprinting random clones: a mathematical analysis. Genomics 2, 231–239 (1988) | Article | PubMed | ChemPort |

Supplementary Information

Supplementary information accompanies this paper.



We thank J.D. Watson for his participation, encouragement and engagement. We thank J. Belmont for discussion of HGMD data. We also thank the following individuals for their technical support: S. Attiya, M. Braverman, J. Brunelle, C. Celone, Z. Chen, A. Sancher, W. Song, and personnel from 454 Sequencing Center and R&D.


Author Information

The CEL files for the Affymetrix 500K Genome array and GPR files for the Agilent_1 and Agilent_2 CGH arrays are deposited in Gene Expression Omnibus under series accession number GSE10668. All SNPs and insertion/deletions from 454-reads are deposited in dbSNP under handle bcmhgsc_jdw; contigs from the assembly of 454-reads not matching the reference genome are deposited in Genbank under accession number ABKV01000000. All 454-reads are deposited in the Trace Archive of the National Center for Biotechnology Information under Center_name = ‘CSHL’ and Center_project = ‘Project JIM’.


Online Methods

DNA sequencing

Genomic DNA was purified from white blood cells from Dr Watson by using the Flexigene DNA kit (Qiagen). Five micrograms of DNA were sheared by nebulization and fractionated on agarose gel to isolate 450–550 base fragments. These were used to construct a single-stranded library that was used as template for single-molecule PCR on 28-μm diameter beads in emulsions3. The amplified template beads were recovered after emulsion breaking and selective enrichment. Sequencing primer was annealed to the template and the beads were incubated with Bst DNA polymerase, apyrase and single-stranded binding protein. A slurry of the template beads, enzyme beads (required for signal transduction) and packing beads (for Bst DNA polymerase retention) was loaded into the wells of a 70mm×75mm picotiter plate. The picotiter plate was inserted in the flow cell and subjected to pyro-sequencing on the Genome Sequencer FLX instrument (454, Inc.).

The Genome Sequencer FLX flows 100 cycles of four solutions containing either dTTP, αSdATP, dCTP and dGTP reagents, in that order, over the cell. For each dNTP flow, a single 38-s image was captured by a CCD (charge-coupled device) camera on the sequencer. The images were processed in real time to identify template-containing wells and to compute associated signal intensities. The images were further processed for chemical and optical cross-talk, phase errors and read quality before base calling was performed for each template bead.

Mapping 454-reads to reference genome

We generated sequence with 234 runs on Genome Sequencer FLX instruments (454 Inc.), which produced over 105million bases per run. Reads were aligned to the human reference genome, NCBI build 36 (http://hgdownload.cse.ucsc.edu/goldenPath/hg18/bigZips/), using BLAT. All but 1.5million reads found one or more match locations in the reference genome. The best match in the genome was used as the location for the reads with multiple matches. Poor-quality alignments were defined as those reads aligning over less than 90% of their length, or with more than four substitutions or insertions/deletions with respect to the reference, or reads that matched two locations with nearly equal match score. Ninety-three million reads comprising 7.4-fold coverage (Fig. 1a, see also Supplementary Fig. 2) passed the filtering criteria and were realigned to local genome segments (41kb each) using Cross_match software. The limitation of a 41-kb genomic fragment placed an upper limit on the sizes of indels that could be detected.

Filtering criteria for SNPs

Mismatch base positions found among the 454-reads were scored using a scaling of the associated error probabilities (Q, see ‘Scoring system for mismatch base positions’ in Supplementary Information). The variant score, Sv, was the sum of scaled 454 Q values. Only variant positions with scores Sv28 were considered. In addition, the ratio of variant bases to total coverage was required to be not less than 0.2.

Known SNPs were associated with homopolymer runs of more than 5bp less than 3% of the time, whereas novel SNPs were associated 33% of the time. Therefore novel variants were removed if they were associated with a homopolymer run of more than 5bp within 13 bases of the SNP; a novel variant was also removed if it was associated with a 5-bp homopolymer run and Sv54 (see ‘Filtering, criteria for SNPs’ in Supplementary Information).

Genotyping with sequence data

The sensitivity of detecting heterozygous SNPs by whole-genome shotgun sequencing is limited by the depth-coverage. If the average depth-coverage is C, the coverage k for each base of the genome approximately follows the Poisson distribution21:

Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

For each heterozygous SNP site of the diploid genome, covered by K reads, the number of reads i representing one of the two alleles follows the binomial distribution:

Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Given that a heterozygous SNP call required observation of at least two reads from both alleles at the SNP site, the sensitivity of detecting heterozygous SNPs was computed based on the two statistical distributions described above (Supplementary Fig. 4).

Filtering criteria for insertions and deletions

Indels were often associated with short tandem repeats sequences, which caused ambiguity in sequence alignments. Among separately aligned reads, indels in close proximity to one another may represent the same event. Based on our analysis of the spacing between indels, a given deletion or insertion is grouped with the previous one if: (1) the two events are the same type (insertion or deletion); (2) the ratio of the smaller to the larger is greater than or equal to 0.8; (3) the distance between the start coordinates is less than 15bp for indels larger than 6bp, or seven times the indel size for indels less than or equal to 6bp. Furthermore, we required valid indels to be supported by at least two reads and have a ratio of variant to reference greater than 0.25. Errors in measurement of homopolymer length were a source of systematic error for indels one base in length, so they were ignored for this study.

Analysis of ‘no-hit’ reads

A total of 169,643 contigs were assembled with a total size of 48Mb and an N50 size (the size at which 50% of the genome is contained within contiguous sequences of this size or greater) of 296bp. Human repeats in the contigs were masked using RepeatMasker, and contigs containing fewer than 100 contiguous bases of unique sequence were set aside. The remaining110,353 contigs spanned 29Mb, with an N50 size of 267bp; 1,294 contigs were longer than 1,000bp, and the longest was 10,724bp.

We used Mega BLAST (http://www.ncbi.nlm.nih.gov/blast/megablast.shtml) with the ‘expect’ parameter set to 10-30 to compare these contigs to a human mRNA sequence database of over 40,000 sequences (http://hgdownload.cse.ucsc.edu/goldenPath/hg18/bigZips/mrna.fa.gz). Significant matches were found to 417 mRNA sequences, which had no map coordinates on build 36. We selected from this set 104 mRNA that matched 886 contigs with greater than 96% identity, and which were covered across more than 40% of the mRNA length. The contigs matching these mRNA sequences ranged in size from 296 to 5121bp. The 104 mRNA sequences were compared with the reference genome using BLAT to confirm they did not have a matching gene on the reference genome. Forty-four were eliminated by this test; 27 had a partial hit, but the genomic match and the contig match did not overlap on the mRNA sequence; 33 of the mRNA sequences had no hit.

Comparative genome hybridization

For the Agilent 244K array, the Human Genome CGH 244K Array (Agilent Technologies, Inc.) contains 238,459 formatted 60-base oligonucleotides, representing a compiled view of the human genome at an average resolution of 9kb. DNA digestion, labelling and hybridization were performed according to the manufacturer’s instructions, with minor modifications. Two separate experiments differed in the reference DNA used for comparison: ‘Agilent_1’ used a standard reference caucasian male (Kleberg Cytogenetics Laboratory, Baylor College of Medicine); ‘Agilent_2’ used a caucasian male, NA10851, Coriell Institute for Medical Research. For the Nimblegen HD2 array, we tested a second sample of experimental DNA co-annealed with reference DNA, Coriell Institute for Medical Research number NA10851, to a NimbleChip HD2 Array (NimbleGen Systems, Inc.) in collaboration with NimbleGen Systems. The HD2 array has 2.1million oligonucleotides, each between 50 and 75 bases, with a reported resolution of about 5kb. Log2 ratios were analysed for variation in copy number using NimbleGen SignalMap software.

Affymetrix Gene Chip 500

Duplicate genomic DNA samples from lymphocytes, 250ng each, were annealed to the Affymetrix 250K NspI and 250K StyI arrays according to the manufacturer’s protocol (see ‘Affymetrix Gene Chip 500’ in Supplementary Information for further details).


These links to content published by NPG are automatically generated.


Toward a malaria haplotype map

Nature Genetics News and Views (01 Jan 2007)

Readers' Comments

If you find something abusive or inappropriate or which does not otherwise comply with our Terms and Conditions or Community Guidelines, please select the relevant 'Report this comment' link.

  1. #64495
    2014-11-19 05:44 AM
    Miguel Romero said:

    Dr. Watson's genome appears to contain a 135 bp sequence belonging to the retrovirus HIV-1. This was revealed by BLASTN testing a 143 bp DNA Contig48983 whole genome shotgun sequence not present in the Human Reference Genome but present in Dr. Watson(1) against the HXB2 reference genome (Accession Numbers ABKV01048903.1 and K03455.1 respectively). BLASTN returned an alignment bearing a 126/135(93%) identity, query cover 94%, no gaps and an expect value of 5X10-55. This sequence is nucleotides 7464-7498 in the HIV-1 env gp120/160 protein coding region and has only an infinitesimal probability of being a chance finding(2). The sequence is similar in length to another HIV-1 env product, the 142 bp DNA amplified by HIV-1 primers SK68/SK69 in breast, ovarian, prostate and other cancers(3) (Accession Number AF048844.1). Could Dr. Watson's DNA have been contaminated by HIV-1 before or during sequencing?(4). If not does this raise the possibility that factor(s) common to aging and cancer may result in modifications in what amounts to tiny portions of human DNA?


    1. www.ncbi.nlm.nih.gov/nuccore/ABKV01048903.1?report=GenBank
    2. www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/1998/III/HXB2.pdf
    3. Rakowicz-Szulczynska EM, Jackson B, Snyder W. Prostate, breast and gynecological cancer markers RAK with homology to HIV-1. Cancer Lett. Feb 27 1998;124:213-223.
    4. Romero Fern�ndez-Bravo M. Contamination of genomic databases by HIV-1 and its possible consequences. A study in Bioinformatics. 2014. http://openaccess.uoc.edu/webapps/o2/handle/10609/31361

    Report this comment

  2. #67241
    2015-11-06 04:12 AM
    Miguel Romero said:

    My comment 1 posted in November 2014 reported the presence of a 135 bp nucleotide sequence in the genome of Dr. James Watson that aligns with the 7464-7598 region of the HIV-1 env (gp120/160) gene. Subsequent BLASTN testing reveals additional high identity sequences between Dr. Watson's genome and the HIV-1 LTRs and p17 and p51 (reverse trans criptase) genes 2. On the one hand these extra data lend further weight to the possibility of contamination. However on the other hand, they may also signal cause for caution now that the CDC has altered its recommendations for HIV diagnosis [3,4]. HIV immunoassays are no longer to be confirmed by Western blot analysis "and nonreactive or indeterminate on the antibody differentiation assay proceed to HIV-1 nucleic acid testing for resolution". If contamination of DNA by HIV-1 sequences is as widespread as other data suggest, 5 then the same may be anticipated in HIV nucleic acid testing facilities.

    1. http://www.nature.com/nature/journal/v452/n7189/full/nature06884.html#comments

    2. https://goo.gl/kBmPzP

    3. Branson BM, Owen SM, Wesolowski LG, Bennett B, Werner BG, Wroblewski KE, Pentella MA: Laboratory testing for the diagnosis of HIV infection: updated recommendations, Centers for Disease Control and Prevention and Association of Public Health Laboratories 2014. http://stacks.cdc.gov/view/cdc/23447

    4. It's time to dump the Western blot. NEJM Watch 2012.

    5. Romero Fern�ndez-Bravo M 2014. Contamination of genomic databases by HIV-1 and its possible consequences. A study in Bioinformatics.

    Report this comment

Add your own comment

This is a public forum. Please keep to our Community Guidelines. You can be controversial, but please don't get personal or offensive and do keep it brief. Remember our threads are for feedback and discussion - not for publishing papers, press releases or advertisements.

You need to be registered with Nature and agree to our Community Guidelines to leave a comment. Please log in or register as a new user. You will be re-directed back to this page.